To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer

Lung Cancer Clinical Trial

Official title:

Molecular Typing System for Early Screening and Diagnosis of Lung Cancer Combined With Liquid Biopsy Technology

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05432128
• Other study ID #: 2019YFC1315803
• Status: Recruiting
• Start date: January 1, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: April 2024
• Source: Singlera Genomics Inc.
• Contact: Meng Yang, Bachelor
• Phone: 18618307980
• Email: 1943826591[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This topic to take large multicenter study real world, the advanced liquid biopsy will ctDNA methylation detection technique is applied to pulmonary nodules differential diagnosis and early lung cancer screening, validation of early lung cancer screening and diagnosis of molecular classification system model, the feasibility of the development of early lung cancer screening and diagnosis of molecular classification system, improve its early screening early detection accuracy and efficiency, Improve the survival status of lung cancer high-risk population. At the same time, this project combined AI analysis technology of LDCT image results with ctDNA methylation detection, so as to overcome false negatives caused by the deficiency of ctDNA methylation detection technology in sensitivity, specificity, stability and flux, and correct false positive results that may be caused by AI analysis technology of LDCT image results. The combination of the two can avoid missed diagnosis and over - examination and over - treatment.

Description:

1. All patients underwent low-dose CT pulmonary nodule AI detection and peripheral blood ctDNA methylation detection at baseline

2. Follow-up plan: Low-risk and medium-risk nodules and some high-risk nodules (5-10mm) were followed up. 10ml peripheral blood was collected from each follow-up and stored for testing until the end of the study. The high-risk nodules over 10mm were evaluated by the expert group and the patients were informed by biopsy or surgical resection. Histopathological diagnosis was made and compared with ctDNA methylation results to analyze the sensitivity and specificity of ctDNA methylation markers of lung cancer.

3. Endpoint: Tissue samples were pathologically diagnosed as benign or malignant.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients with pulmonary nodules confirmed by chest CT are not limited to single nodules;

2. Nodule diameter 5-30mm

3. Nodules include solid, semi-solid and ground glass nodules;

4. Age 18-75, no gender limitation;

5. The newly diagnosed patients did not receive surgery, radiotherapy, chemotherapy, targeted therapy or other tumor-related interventions;

6. Sign informed consent.

Exclusion Criteria:

1. Patients with diagnosed lung cancer and extrapulmonary malignant tumor;

2. Pulmonary sarcoidosis, pulmonary vasculitis, pulmonary tuberculosis;

3. Patients with poor compliance are expected to be unable to complete follow-up according to the study protocol;

4. Major trauma requiring blood transfusion occurred within one week before enrollment;

5. Pregnant and lactation patients.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
China	China-Japan Friendship Hospital	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Singlera Genomics Inc.	China-Japan Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To develop a molecular typing system for early screening and diagnosis of lung cancer	The feasibility of the molecular typing system model for early screening and diagnosis of lung cancer was verified through clinical studies, which significantly improved the accuracy and efficiency of early screening and early diagnosis, and improved the survival status of high-risk population of lung cancer.	assessed up to 36 months
Primary	AI technology was combined with ctDNA methylation detection technology	In addition to overcoming false negatives caused by deficiencies in sensitivity, specificity, stability and flux of ctDNA methylation detection technology, and correcting false positive results that may be caused by AI, the combination of the two can avoid missed diagnosis, over-examination and over-treatment.	assessed up to 36 months